YieldMax AI & Tech Portfolio Option Income ETF vs 10X Genomics Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.92, while 10X Genomics Inc trades at $58.47 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| GPTY | TXG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $58.57 |
52-Week Low | $34.73 | $11.34 |
Market Cap | — | $7.61B |
Enterprise Value | — | $7.14B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →